- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Joe O'Sullivan Explains Education of Patients and Physicians on Molecular Therapies
Physicians using molecular therapies need to be educated on where the therapies are best used during treatment, and patients need to understand that the radiation is safe for those around them, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
Physicians using molecular therapies need to be educated on where the therapies are best used during treatment, and patients need to understand that the radiation is safe for those around them, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
When using molecular therapies, is there a need for education among both patients and providers?
I think there is a need for education among the providers, first of all, in understanding where therapies like this should be best used. And they need to be used, if they’re used as a single agent, they need to be used at a time when the prostate cancer has not yet spread to visceral metastases—for example, liver or lung. So it needs to be bone only. And they also need to understand that a positive bone scan, a technetium bone scan, is required in order to say that, “this particular patient would benefit from this approach.” Because, if it’s not seen on a technetium scan, it’s unlikely that much radium will get into the bones.
Now, with regards to patient education, mostly it’s explaining to them what’s involved, making sure that they know there really is no radiation risk to anyone around them, because some patients worry about a radioactive treatment and that it might affect the people around them. Part of the education is reassuring them that this particular type of radiation is safe with other people.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More
